GE HealthCare (GEHC): Record Orders, Record Backlog — And The Margin Still Went DOWN

GE HealthCare Technologies (GEHC) Q2 2026 — GE HealthCare (GEHC) — the medical imaging company spun out of General Electric in January 2023 — reported Q2 2026 (quarter ended June 30) on July 29. Revenue was $5.295B (+5.7%, +3.5% organic), GAAP diluted EPS $1.24 vs $1.06, and adjusted EPS $1.13 vs the ~$1.04 consensus. Organic orders grew a record 11.1%, book-to-bill hit 1.15x and backlog reached a record $23.9B. The stock jumped ~12% to $71.90, then gave part of it back to ~$69.12. Why we're cautious: adjusted EBIT margin FELL 40 bps to 14.2%, adjusted EBIT grew only 2.9% on 5.7% revenue growth, and the beat was helped by IEEPA tariff refunds and a ~17% tax rate. Our free-cash-flow DCF lands at ~$57 vs $69.12. Our call: HOLD, 3/5. A genuinely strong demand quarter attached to a genuinely weak profit quarter. The good: record organic orders +11.1% (vs 3.4% a year ago) across every segment, 1.15x book-to-bill, record $23.9B backlog — orders lead revenue by a year or more in imaging. Pharmaceutical Diagnostics grew 15.6% to $843M at a 29.6% EBIT margin; Advanced Imaging Solutions grew 7.9% to $3.771B with margin up 90 bps to 13.9%. But three things sit underneath. First, operating leverage went the wrong way: revenue +5.7% but adjusted EBIT only +2.9% to $750M, margin DOWN 40 bps to 14.2%, hurt by ~$250M of full-year inflation from memory chips, oil and freight. Second, the quality of the beat: $129M of IEEPA tariff refunds ($106M from 2025 excluded from adjusted EBIT, $23M from 2026 included) and a ~17.2% GAAP tax rate against 20-21% guidance — the release itself credits 'tariff refunds as well as a lower tax rate.' Third, Patient Care Solutions collapsed: revenue -13.3% to $675M, segment EBIT NEGATIVE $26M, a -3.8% margin down 1,150 bps, and management is now 'reviewing strategic options' for it. Also: Imaging and Advanced Visualization merged into one segment (GEHC now reports three); CFO Jay Saccaro departs August 14 with George Newcomb interim; China is guided to DECLINE on volume-based procurement. FY2026 guidance was REAFFIRMED, not raised: 3-4% organic growth, 15.4-15.7% adjusted EBIT margin, $4.80-5.00 adjusted EPS, ~$1.6B free cash flow. That guide is the debate. First-half adjusted EBIT margin was 13.8%, so the back half must run above 17%. First-half free cash flow was $180M ($458M operating cash flow less $278M capex), so the back half must produce ~$1.42B — about 89% of the year in two quarters — and Q2's $168M of operating cash flow included a $107M tariff refund. We value the cash: ~$4.05B of FY26 adjusted EBITDA converts to only ~$1.6B of free cash flow after ~$550M cash interest, ~$500M cash taxes, ~$820M working capital and other, and ~$580M capex. Grow $1.5B of normalized free cash flow 8% for five years then 5%, discount at 9%, subtract ~$8.0B net debt, divide by ~455M shares: ~$57, about 21% below the price. A reverse DCF says $69.12 needs ~5.0% free-cash-flow growth forever against 3-4% guided organic growth. THE CALL: HOLD (3/5, RECORD ORDERS AND A RECORD BACKLOG — BUT THE MARGIN WENT BACKWARDS AND THE CASH ISN'T THERE YET) — base-case value ~$57.00 vs ~$69.12 today. What to watch: Q3 adjusted EBIT margin printing above 16%, which would show the back-half ramp is real; Q3 free cash flow of $700M or more; and an announced sale or exit of Patient Care Solutions, which would add roughly a point of consolidated margin. The risks: a full-year guidance cut, which becomes likely if Q3 shows no margin expansion; memory-chip and freight inflation running past the ~$250M assumption; China deteriorating faster than the guided decline; and a permanent CFO hired externally who rebases the numbers. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.